Development of a drug screening system using three-dimensional cardiac tissues containing multiple cell types

Maki Takeda, Shigeru Miyagawa, Emiko Ito, Akima Harada, Noriko Mochizuki-Oda, Michiya Matsusaki, Mitsuru Akashi & Yoshiki Sawa

We hypothesized that an appropriate ratio of cardiomyocytes, fibroblasts, endothelial cells, and extracellular matrix (ECM) factors would be required for the development of three-dimensional cardiac tissues (3D-CTs) as drug screening systems. To verify this hypothesis, ECM-coated human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), ECM-coated cardiac fibroblasts (CFs), and uncoated cardiac endothelial cells (CEs) were mixed in the following ratios: 10:0:0 (10CT), 7:2:1 (7CT), 5:4:1 (5CT), and 2:7:1 (2CT). The expression of cardiac-, fibroblasts-, and endothelial-specific markers was assessed by FACS, qPCR, and immunostaining while that of ECM-, cell adhesion-, and ion channel-related genes was examined by qPCR. Finally, the contractile properties of the tissues were evaluated in the absence or presence of E-4031 and isoproterenol. The expression of ECM- and adhesion-related genes significantly increased, while that of ion channel-related genes significantly decreased with the CF proportion. Notably, 7CT showed the greatest contractility of all 3D-CTs. When exposed to E-4031 (hERG K channel blocker), 7CT and 5CT showed significantly decreased contractility and increased QT prolongation. Moreover, 10CT and 7CT exhibited a stronger response to isoproterenol than did the other 3D-CTs. Finally, 7CT showed the highest drug sensitivity among all 3D-CTs. In conclusion, 3D-CTs with an appropriate amount of fibroblasts/endothelial cells (7CT in this study) are suitable drug screening systems, e.g. for the detection of drug-induced arrhythmia.

Many drugs are withdrawn from the market due to adverse side effects. Cardiotoxicity, including cytotoxicity and proarrhythmic effect, is a major cause of discontinuation of drug development.

The current screening methods are based on animal models, but species-specific differences in drug effectiveness and safety may be observed. Moreover, also due to growing political and social pressure, various attempts to develop systems alternative to animal models have recently been made.

A particularly promising approach is represented by innovative in vitro drug screening systems based on human cells, including human induced pluripotent stem cells (hiPSCs).

We have previously developed a new drug screening system to test drug-induced cardiotoxicity in vitro, based on hiPSC-derived three-dimensional cardiac tissues (3D-CTs), which showed good response to some cardiovascular agonists. However, the contractile properties of these systems are still poor compared to those of myocardial tissues in vivo. In addition, we previously observed that although E-4031 administration decreases in vitro contractility, it does not elicit arrhythmia or Torsades de Pointes (TdP), which are normally observed in vivo under the same conditions. In light of the above results, we concluded that 3D-CTs did not completely reproduce the characteristics of in vivo myocardial tissues and that, therefore, appropriate adjustments may be necessary before using 3D-CTs as accurate tools for drug response prediction.

Myocardial tissues contain various types of cells and extracellular matrix (ECM) components, transducing receptor-mediated signals into cells, ultimately maintaining the homeostasis of cardiac tissues. Signaling events involving the ECM and cardiomyocytes have a great impact on the performance of 3D-CTs, and are, in...
turn, strongly affected by the cellular composition. To date, the assembly of 3D-CT structural components has not been optimized for drug screening.

In this study, 3D-CTS containing various proportions of hiPSC-derived cardiomyocytes (hiPSC-CMs), human cardiac fibroblasts (CFs), and human cardiac microvasculature endothelial cells (CEs) were constructed, and their performance as drug screening systems was evaluated in relation to the cellular composition.

Results

Structural characteristics of 3D-CTS. The 3D-CTS formed a multi-layered shape with a thickness of 50–100 µm (Fig. 1A). After 5 days of culture, 3D-CTS were dispersed and their cellular composition was assessed by FACS (Fig. 1B) and qPCR (Fig. 1C). The cellular composition of 3D-CTS was maintained after ~ 5 days of culture. The expression of cTnT, an hiPSC-CM marker, in 7CT, 5CT, and 2CT was 0.8-fold, 0.6-fold, and 0.2-fold that of 10CT, respectively. The expression of vimentin (reflecting the proportion of CFs) in 7CT, 5CT, and 2CT was 4.7-fold, 6.2-fold, and 7.7-fold that of 10CT, respectively (Fig. 1C).

The structure of the 3D-CTS was characterized by immunohistological staining of cardiac-, fibroblasts-, endothelial-specific and ECM proteins (Fig. 2A–E). Cardiac-specific proteins such as cTnT and a-actinin were clearly expressed in all 3D-CTS, and their level increased with the proportion of hiPSC-CMs (Fig. 2A–C). Notably, the myosin heavy chain isoform, β-MHC, was predominantly expressed in cardiac myocytes, whereas no significant difference was found between 3D-CTS (Figs. 1D and 2D). The expression of ECM proteins such as fibronectin and laminin increased with the proportion of fibroblasts (Fig. 2E). The cell-occupied area strongly correlated with the ratio of mixed cells (cTnI-positive cell area/vimentin-positive cell area: 10CT, 89 ± 4.4%/11 ± 4.4%; 7CT, 73 ± 16%/27 ± 16%; 5CT, 37 ± 7.4%/63 ± 7.4%; 2CT, 28 ± 16%/72 ± 16%). In 5CT and 2CT with a high fibroblast content, the endothelial cells were extended compared to 7CT (CD31-positive cell area: 5CT, 2.4-fold; 2CT, 2.1-fold, respectively). In 3D-CTS, cardiomyocytes were located at the center, the fibroblasts at the periphery, and the endothelial cells were present to fill the space between cardiomyocytes and fibroblasts (Fig. 2A,B).

Gene expression in 3D-CTS. The expression of genes for ECM components and ion channels was quantitatively evaluated by qPCR (Fig. 3). The expression of ECM components increased with the presence of fibroblasts and endothelial cells. In particular, the following expression differences were observed in 3D-CTS: collagen 1, 50-fold (P < 0.01), 70-fold (P < 0.01), and 90-fold (P < 0.01), respectively; collagen 3, 24-fold (P < 0.01), 33-fold (P < 0.01), and 49-fold (P < 0.05), respectively; fibronectin, 30-fold (P < 0.05), 49-fold (P < 0.05), and 61-fold (P < 0.05), respectively; and laminin, 1.5-fold, 2.0-fold, and 1.9-fold (P < 0.01), respectively. Moreover, the transcripts of gap junction protein alpha 1 (GJA1) and N-cadherin increased with the presence of fibroblasts and endothelial cells [GJA1: 2.3-fold (P < 0.05), 3.0-fold (P < 0.05), and 3.4-fold (P < 0.05) compared to 10CT in 7CT, 5CT, and 2CT, respectively; N-cadherin: 1.7-fold (P < 0.05), 2.0-fold (P < 0.01), and 2.0-fold (P < 0.01) in 7CT, 5CT, and 2CT, respectively]. On the other hand, the expression of ion channel-related genes increased with the proportion of hiPSC-CMs [KCNQ1, potassium Voltage-Gated Channel Subfamily Q Member 1: 1.0-fold, 0.66-fold (P < 0.01), and 0.23-fold (P < 0.01) in 7CT, 5CT, and 2CT, relative to 10CT, respectively; KCNH2, potassium voltage-gated channel subfamily H member 2: 0.78-fold, 0.55-fold (P < 0.01), and 0.18-fold (P < 0.01); SCN5A, sodium voltage-gated channel alpha subunit 5: 0.91-fold, 0.69-fold, and 0.23-fold (P < 0.01); CACNA1H, calcium voltage-gated channel subunit alpha 1 H: 0.95-fold, 0.83-fold (P < 0.05), and 0.73-fold; CACNA1C, calcium voltage-gated channel subunit alpha1 C: 1.1-fold, 0.90-fold, and 0.35-fold (P < 0.01); and SERCA2a, sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase 2a: 0.78-fold (P < 0.01), 0.71-fold (P < 0.01), and 0.56-fold (P < 0.01)]. In 7CT, the genes for ion channels were expressed at a slightly lower (or equivalent) level compared to those in 10CT.

Contractile properties of 3D-CTS. The contractile properties of 3D-CTS were assessed by the Cell Motion Imaging System (Fig. 4A). 7CT showed remarkably better contractile properties than did the other 3D-CTS. The beating rate was 31 ± 8.2/min in 10CT, 23 ± 4.9/min in 7CT (P < 0.01 vs. 10CT), 23 ± 5.0/min in 5CT (P < 0.01), and 30 ± 10/min in 2CT (Fig. 4B). The contraction velocity was 17 ± 5.0 µm/s in 10CT, 39 ± 33 µm/s in 7CT (P < 0.01), 24 ± 19 µm/s in 5CT, and 6.3 ± 2.6 µm/s in 2CT (Fig. 4C). The relaxation velocity was 5.9 ± 2.4 µm/s in 10CT and 30 ± 10/min in 2CT (Fig. 4B). The contraction-relaxation peak interval (CRPI) was 4.7-fold, 6.2-fold, and 7.7-fold that of 10CT, respectively (Fig. 4C).

Contractile properties of 3D-CTS in response to E-4031 or isoproterenol. The effects of E-4031 (Fig. 5) and isoproterenol (Fig. 6) on the contractile properties of 3D-CTS were assessed by the Cell Motion Imaging System (Fig. 5A). E-4031 caused the prolongation of cardiac repolarization (Fig. 5B). 10CT exposure to 100 nM E-4031 caused a significant increase in the contraction-relaxation peak interval (CRPI) (1.3-fold vs. vehicle control, P < 0.05) and in the contraction-relaxation duration, corrected with Fridericia's formula (CRDcf) (1.4-fold, P < 0.01), with a significant decrease in the inter-region correlation coefficient from 0.94 to 0.91 (P < 0.05). An abnormal waveform was observed in 45% of the samples exposed to 100 nM E-4031. 10CT tended to increase the beating rate and relaxation velocity at high concentrations (Fig. 5C–G). 7CT exposure to 10 nM E-4031 caused a significant decrease in the relaxation velocity (0.68-fold vs. vehicle control, P < 0.01) and inter-region correlation coefficient (from 0.96 to 0.94, P < 0.01), and a significant increase in CRPI (1.8-fold, P < 0.01) and CRDcf (1.3-fold, P < 0.01). 5CT treatment with 3 nM E-4031 caused a significant decrease in the relaxation velocity (0.74-fold, P < 0.01), and a significant increase in CRPI (1.5-fold, P < 0.05) and CRDcf (1.3-fold, P < 0.01). 5CT exposure to 100 nM E-4031 substantially decreased
the inter-region correlation coefficient (from 0.94 to 0.63, P < 0.01) (Fig. 5C–G). An abnormal waveform was observed in 60% of the 5CT samples exposed to 10 nM E-4031 and in 100% of the samples exposed to 100 nM E-4031. 2CT exposure to 10 nM E-4031 resulted in a significant decrease in the relaxation velocity (0.29-fold,
P < 0.01) and a significant increase in CRPI (1.3-fold, P < 0.05) and CRDcf (1.5-fold, P < 0.01). 2CT exposure to 30 nM E-4031 decreased the inter-region correlation coefficient from 0.85 to 0.30 (P < 0.01). An abnormal wave-
form or beating arrest was observed in 72% of the 2CT samples exposed to 10 nM E-4031 and in 100% of the samples exposed to 100 nM E-4031. 2CT tended to increase the beating rate at 3 or 10 nM E-4031 (Fig. 5C–G).

Isoproterenol generally increases beating rate, contraction velocity, and relaxation velocity in cardiomyocytes. 10CT, 7CT, and 5CT exposure to 10 nM isoproterenol led to a significant increase in the beating rate (1.5-fold, \( \text{P} < 0.01 \), 1.6-fold, \( \text{P} < 0.01 \), and 1.3-fold, \( \text{P} < 0.05 \), respectively vs. vehicle control) and relaxation velocity (1.6-fold, \( \text{P} < 0.01 \), 1.4-fold, \( \text{P} < 0.01 \), and 1.3-fold, \( \text{P} < 0.01 \), respectively). 2CT exposure to 10 nM isoproterenol induced significant increase in the beating rate (1.2-fold, \( \text{P} < 0.05 \)), whereas no significant difference in relaxation velocity was observed. Contraction velocity significantly increased in 10CT exposed to 3 nM isoproterenol (1.3-fold, \( \text{P} < 0.05 \)), in 7CT exposed to 30 nM isoproterenol (1.3-fold, \( \text{P} < 0.05 \)), in 5CT exposed to 100 nM isoproterenol (1.2-fold, \( \text{P} < 0.05 \)), and in 2CT exposed to 30 nM isoproterenol (1.2-fold, \( \text{P} < 0.01 \)). At 1 nM isoproterenol in 10CT and 7CT, CRP1 was significantly decreased (0.88-fold, \( \text{P} < 0.01 \), and 0.88-fold, \( \text{P} < 0.01 \), respectively),

Figure 3. Expression of ECM and ion channel-related genes in 3D-CTs. The mRNA expression of collagen 1, collagen 3, fibronectin, laminin, GJA1, N-cadherin, KCNQ1, KCNH2, SCN5A, CACNA1H, CACNA1C, and SERCA2 in 3D-CTs, as determined by qPCR. All qPCR data are shown as relative values compared to 10CT. *\( \text{P} < 0.05 \), **\( \text{P} < 0.01 \), as compared to 10CT.
whereas at 3 nM isoproterenol in 5CT and 2CT, CRP significantly decreased (0.83-fold, P < 0.01, and 0.90-fold, P < 0.01, respectively). The inter-region correlation coefficient was not affected by isoproterenol in any of the 3D-CTs (Fig. 6A–E).

**Figure 4.** Contractile properties of 3D-CTs. (A) Representative contraction waveform of 3D-CTs. (B) Beating rate. (C) Contraction velocity. (D) Relaxation velocity. (E) Inter-region correlation coefficient. *P < 0.05, **P < 0.01, as compared to 10CT.
Discussion
In this study, we created three-dimensional cardiac tissues containing various proportions of hiPSC-CMs,
fibroblasts, and endothelial cells, and investigated their pathophysiology and suitability as a drug screening tool. The expression of cardiac-specific proteins and ion channel-related genes in 3D-CTs increased with the proportion of hiPSC-CMs, whereas the expression of ECM components and cell-adhesion factors depended on the proportion of fibroblasts and the presence of endothelial cells. 7CT exhibited the best contractility in the absence of any cardiovascular agonists. When exposed to low concentrations of proarrhythmic drugs, 7CT and 5CT exhibited a decrease in relaxation velocity and an increase in CRPI and CRDcf compared to 10CT. In particular, 7CT and 5CT showed higher reactivity to these drugs than did the other 3D-CTs. In addition, when exposed to a positive inotropic drug, 10CT and 7CT exhibited the strongest and dose-dependent changes in contraction-relaxation velocity and CRPI.

**Figure 6.** Contractile properties of 3D-CTs after addition of isoproterenol. (A) Beating rate. (B) Contraction velocity. (C) Relaxation velocity. (D) CRPI. (E) Inter-region correlation coefficient. *P < 0.05, **P < 0.01, as compared to the vehicle control.
Overall, 7CT and 5CT showed better contractility than did 10CT and 2CT, indicating that 3D-CTs with extremely low or high proportions of fibroblasts may not be suitable for drug screening.

Fibroblasts and endothelial cells directly and indirectly regulate cardiac electrophysiology. The interaction between cardiomyocytes and these cells allows for electrical propagation in detached cardiomyocytes, and promotes electrical conduction. The binding of cardiomyocytes to depolarized fibroblasts increases the resting membrane potential, which may result in increased conduction velocity, provided that fibroblasts are present at the appropriate density 

In addition, the adhesion of these cells to cardiomyocytes affects the electrical conduction. By producing ECM components and matrix metalloproteinases, fibroblasts and endothelial cells promote cell-to-cell adhesion and fill the gaps between cells. Insufficiently strong cell-to-cell adhesion results in increased cardiomyocyte resting membrane potential and conduction velocity. An excessive proportion of fibroblasts or endothelial cells may result in abnormally strong cell-to-cell adhesion, possibly slowing down, and eventually impairing, electrical conduction, as suggested by previous reports. Therefore, it can be concluded that an optimal proportion of fibroblasts and endothelial cells is crucial to preserve electrical conduction.

Our results showed that 2CT, which is rich in fibroblasts, highly expressed ECM components and exhibited the weakest contractility. 2CT also showed a lower inter-region correlation coefficient than did the other 3D-CTs, indicating the synchronization of cardiomyocyte contraction. 2CT may not be suitable as a model to study contraction, due to the low number of cardiomyocytes and the excessive number of fibroblasts, causing insufficient contractility and impaired conduction, respectively.

7CT, in which the proportions of hiPSC-CMs, CFs and CEs were 70%, 20% and 10%, respectively, showed the best contractile performance. In this 3D-CT, the proper strength of cell-to-cell adhesions and the appropriate proportions of ECM factors, fibroblasts, and endothelial cells ensured an optimal balance between contraction and electrical conduction.

In myocardial tissue in vivo, cardiomyocytes and fibroblasts account for 30% and 70% of the total cell number, respectively, with 70% of the cell volume accounted for by cardiomyocytes and 30% by fibroblasts. In our optimal 3D-CT model, 70% of the cells were cardiomyocytes and 20% were fibroblasts, while the 80% of the cell volume was constituted by cardiomyocytes and 20% by fibroblasts, presenting a model histologically comparable to the native heart.

Next, the suitability of the different 3D-CTs as drug screening models was explored. To evaluate proarrhythmic and negative chronotropic effects, a HERG potassium channel blocker, E-4031, acting on ion channels at the cell surface, was employed. Our results showed that 7CT and 5CT, with CF proportions of 20% and 40%, respectively, reproduced proarrhythmic and negative chronotropic effects in an E-4031 dose-dependent manner, whereas 10CT, containing only hiPSC-CMs, showed little response to E-4031. Previous studies reported that TdP do not occur in cardiac tissues that contain only cardiomyocytes, in line with our findings.

In the present study, the exposure of 2CT, containing 70% CFs, to a high concentration of E-4031 resulted in progressive weakening and in the eventual stop of contraction. The block of action potential in 2CT might be due to the lack of depolarization in the presence of high E-4031 concentrations. This behavior was different from that observed in vivo, suggesting that 2CT was not suitable for the evaluation of drugs causing QT prolongation.

To evaluate positive inotropic effects, we used isoproterenol, a non-selective beta adrenoceptor agonist, which increases cardiac contractility via catecholamine receptors. Since catecholamine receptors are present in cardiomyocytes, we reasoned that 3D-CTs with a high content of hiPSC-CMs would show a better contractile performance than those with lower hiPSC-CM proportions. As expected, 10CT and 7CT, containing an hiPSC-CM proportion of 100% and 70%, respectively, as well as a high content of cardiomyocytes, exhibited a concentration-dependent increase in contractility after treatment with isoproterenol. Although 7CT exhibited a sensitive response to typical positive and negative inotropic drugs in this study, it is necessary to test this system using more drugs that act through various mechanisms. In addition, we plan to further investigate drug response by analyzing calcium transient, extracellular potential, and contraction force, in addition to tissue contractile motion, to provide a more complete analysis of cellular physiology. In this study, 5CT showed a drug response that showed proarrhythmic and negative chronotropic effects as sensitively as 7CT, suggesting that it may be used as a cardiac fibrosis model in the future.

Standardization of this model for drug screening requires homogeneous cell quantity and quality. In the construction of the described 3D-CTs, the cell proportions can be precisely controlled and, therefore, tissue constructs with approximately the same number of cells can be obtained. Regarding the cellular quality, further optimization is needed to ensure phenotypic homogeneity and controlled maturation of cardiomyocytes after cardiac differentiation.

In conclusion, 3D-CTs with various cellular compositions were tested and 7CT (70% hiPSC-CMs, 20% CFs, 10% CEs) showed optimal contractility and good response to inotropic drugs. In vitro cellular models capable of recapitulating cardiac physiology are strongly desired for drug screening. Thus, 3D-CTs with appropriate cellular combinations are reliable systems for in vitro drug screening.

Methods

Cell culture. HiPSCs (253G1; Riken, Ibaraki, Japan) were cultured in Primate ES Cell medium (ReproCELL, Kanagawa, Japan) containing 4 ng/mL human basic fibroblast growth factor (bFGF; Wako, Osaka, Japan) on mouse embryonic fibroblasts (ReproCELL). Normal human ventricular CFs (NHCFs) and human cardiac microvascular endothelial cells (HMVECs) were purchased from Lonza (Basel, Switzerland) and maintained in FGM-3 BulletKit (Lonza) or EGM-2MV BulletKit (Lonza).

Cardiac differentiation of hiPSCs. Cardiac differentiation was induced as previously described with modifications. In brief, hiPSCs were dissociated using Accumax (Innovative Cell Technologies, San Diego, CA)
CA, USA) and cultured in differentiation medium containing StemPro34 (ThermoFisher Scientific, MA, USA), 2 mM l-Glutamine (ThermoFisher Scientific), 50 μg/ml ascorbic acid (FUJIFILM Wako Pure Chemical, Osaka, Japan), and 1-thioglycerol (Sigma-Aldrich, St. Louis, USA). After embryoid body formation, the culture medium was replaced with differentiation medium containing several human recombinant proteins, including BMP4, activin A, bFGF, vascular endothelial growth factor (R&D Systems, MN, USA), or small molecules such as IWR-1 (FUJIFILM Wako Pure Chemical). HiPSC-CMs were maintained in DMEM (Nacalai Tesque, Kyoto, Japan) containing 10% fetal bovine serum (FBS; Sigma-Aldrich).

Construction of 3D-CTs. 3D-CTs were constructed as previously described.12,31–33 HiPSC-CMs and NHCFs were dissociated with 0.05% trypsin–EDTA (ThermoFisher Scientific) and coated with fibronectin (F; Sigma-Aldrich) and gelatin (G; FUJIFILM Wako Pure Chemical), respectively. The 3D-CTs were prepared by mixing FG-coated hiPSC-CMs, NHCFs, and uncoated HMVECs in the following proportions: 10:0:0 (10CT), 7:2:1 (7CT), 5:4:1 (5CT), and 2:7:1 (2CT). The 3D-CTs (1 × 10^6 cells) were seeded into 6.5-mm transwell inserts with 0.4-μm pore size (Corning, MA, USA) and cultured in DMEM with 10% FBS for 4 or 5 days.

Histological stain. The 3D-CTs were fixed with formalin and embedded in paraffin. The paraffin 3D-CTs blocks were then sectioned (0.5 μm thickness) using a microtome (HM430; ThermoFisher Scientific) and the sections were then stained with hematoxylin–eosin and assessed using a microscope (DM4000B; Leica, Germany).

Flow cytometry. The 3D-CTs were dissociated with 0.05% trypsin–EDTA (ThermoFisher Scientific), fixed with Cytofix fixation buffer (BD Biosciences, Franklin Lakes, NJ, USA), and permeabilized with Perm/Wash buffer (BD Biosciences). The cells were labeled with the primary antibodies anti-cardiac troponin T (cTnT; Santa Cruz Biotechnology, Dallas, TX, USA) and TE-7 (Merk Millipore, Billerica, MA, USA) in Perm/Wash buffer, followed by incubation with secondary antibodies, i.e., AlexaFluor488 goat anti-mouse IgG (ThermoFisher Scientific). The cells were analyzed by a FACS Canto II system (BD Biosciences), and data were analyzed with FlowJo software (Tree Star, Ashland, OR, USA).

Quantitative real-time polymerase chain reaction. Total RNA was extracted from 3D-CTs using a PureLink RNA Mini Kit (ThermoFisher Scientific). Quantitative real-time polymerase chain reaction (qPCR) were performed as previously described.1 All data were normalized using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a control, and assessed using the delta CT method. The expression of β-MHC and α-MHC were normalized using cTnT. All qPCR data are shown as relative values compared to 10CT. The primer sequences are listed in Table 1.

Immunohistochemistry. The 3D-CTs were fixed with 4% paraformaldehyde, embedded in optimal cutting temperature compound (Sakura Finetek Japan, Tokyo, Japan), and sectioned (5–7 μm thick sections) using a cryostat (CM1950; Leica). The 3D-CTs sections were subsequently labeled with the following primary antibodies: anti-cTnT (1:200 dilution; Abcam, Cambridge, UK), anti-sarcomeric alpha-actinin (α-actinin, 1:400; Sigma-Aldrich), and anti-cardiac troponin T (cTnT; Sigma-Aldrich).

Table 1. Sequences of the primers and probes for qPCR. GAPDH glyceraldehyde-3-phosphate dehydrogenase, cTnT cardiac troponin T, MHC myosin heavy chain, GJA1 gap Junction Protein Alpha 1.

| Gene     | Forward primer (5′→3′)                  | Reverse primer (5′→3′)                  |
|----------|-----------------------------------------|-----------------------------------------|
| GAPDH    | GACCTCAACTCATACCGTTGCCA                  | GTGACACGTCTCATGCTGCGGT                  |
| cTnT     | AGCATCTATAACCTGGAGGAGGAGAG              | TGGAGACCTTTCGGTTATTCTGTG                |
| Vimentin | AATTGCCGGAGGAGATGCTCTCA                  | AAAGATGGAGGTGTTTTTGG                   |
| β-MHC    | ACAAGCTGCGAGTAAAGGTC                    | TCAAGATGTGGCGAAGGCTAC                  |
| α-MHC    | CTTCAAAGCTGAGGCGAGCT                   | GCCCTTCTTGTACCTACGCT                   |
| Collagen1| TACCTGATGTCACGCAAACTCCAG                | AAAGACTTGGATGGCGATCCAGGT               |
| Collagen3| AGTCCAGGGAAAAGGTGGTACGG                 | CATTCTCTTAGGGAGCGGAGGA                 |
| Fibronectin | AGACAGTCTGACCCGACTCTCT               | TTCTGCTGGAGGAGGAGTAGAAC               |
| Laminin  | AGGGTATACGTGCTCTCCTTG                  | GCCGTCAAGATGCCACCAAAAT               |
| GJA1     | CAGGGTAGCAGCTTCTTCTCTC                 | ACACCGAGCAGTGAAGATGT                 |
| N Cadherin | TTCATCTCAACCCCATCTCGG                 | TCTACTGCTATGGGCGTCTCAAAAT          |
| KCNQ1    | CTTGCCGAGGGAGCTGACCTG                  | GATCAACATGGAGGCTCC                   |
| KCNH2    | GATAGCGGCCACCTACCAAGGCG                | AGTAGAGCGGGCGTCGATACTCT                |
| SCN5A    | GAGCCACTGTCGGGTGGCTG                   | GATTGGCCAGTTGAGACG                    |
| CACNA1H  | CTATGCTGCGGGTGGAGGT                   | CTCGCGAGGTTGCTCCTCT                   |
| CACNA1C  | JAGTGCAACAAGACCTGCTACAGA              | GAAGGTCATCTCTCTGCTGAGGA               |
| SERCA2   | TTTCCTCAGTATGGTGAGGGAGCAACC         | TTCAGGTTAGTGCGGCGCCACAA               |

GAPDH glyceraldehyde-3-phosphate dehydrogenase, cTnT cardiac troponin T, MHC myosin heavy chain, GJA1 gap Junction Protein Alpha 1.
2. Darpo, B., Nebout, T. & Sager, P. T. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: The international conference on harmonization of technical requirements for registration of pharmaceuticals for human use E14 guideline. J. Clin. Pharmacol. 46, 498–507. https://doi.org/10.1177/0091270006286436 (2006).

3. Ferri, N. et al. Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity. Pharmacol. Ther. 138, 470–484. https://doi.org/10.1016/j.pharmthera.2013.03.005 (2013).

4. Laverty, H. et al. Can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br. J. Pharmacol. 163, 675–693. https://doi.org/10.1111/j.1476-5381.2011.01255.x (2011).

5. Redfern, W. S. et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de points for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32–45. https://doi.org/10.1016/s0008-6363(02)00846-5 (2003).

6. Jacobs, H. et al. Differences in pharmacological activities of the antioxidant flavonoid monoHER in humans and mice are caused by variations in its metabolic profile. Clin. Pharmacol. Ther. 90, 852–859. https://doi.org/10.1002/cpt.2011.200 (2011).

7. Leemans, C. H. C. et al. Animal to human translation: A systematic scraping review of reported concordance rates. J. Transl. Med. 17, 223. https://doi.org/10.1186/s12976-019-1976-2 (2019).

8. Archibald, K., Drake, T. & Coleman, R. Barriers to the uptake of human-based test methods, and how to overcome them. Altern. Lab. Anim. 43, 301–308. https://doi.org/10.1177/0090769X15603050 (2015).

9. Cheluvarpa, R., Scowen, P. & Eri, R. Ethics of animal research in human disease remediation, its institutional teaching; and alternative to animal experimentation. Pharmacol. Res. Perspect. 5, e00332. https://doi.org/10.1002/prp2.332 (2017).

10. Coleman, R. A. Human-based systems in drug and chemical safety testing-toward replacement, the “single R”. Altern. Lab. Anim. 42, 357–366. https://doi.org/10.1177/02611929145200605 (2014).

11. Zhang, B. & Radisic, M. Organ-on-a-chip devices advance to market. Lab Chip 17, 2395–2420. https://doi.org/10.1039/c6lc01554a (2017).

12. Takeda, M. et al. Development of in vitro drug-induced cardiotoxicity assay by using three-dimensional cardiac tissues derived from human induced pluripotent stem cells. Tissue Eng. Part C Methods 24, 56–67. https://doi.org/10.1089/ten.TEC.2017.0247 (2018).

13. Howard, C. M. & Baudino, T. A. Dynamic cell–cell and cell–ECM interactions in the heart. J. Mol. Cell. Cardiol. 70, 19–26. https://doi.org/10.1016/j.yjmcc.2013.10.006 (2014).

14. MacKenna, D., Summerour, S. R. & Villarreal, F. J. Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc. Res. 46, 257–263. https://doi.org/10.1006/cvr.2010.0030-4 (2000).

15. Vliegen, H. W., van der Laarze, A., Cornelisse, C. J. & Eulderink, F. Myocardial changes in pressure overload-induced left ventricular hypertrophy: A study on tissue composition, polyplidization and multinucleation. Eur. Heart J. 12, 488–494. https://doi.org/10.1093/eurheartj/ehy092 (1991).

16. Goldsmith, E. C., Bradshaw, A. D., Zile, M. R. & Spina, D. E. G. Myocardial fibroblast–matrix interactions and potential therapeutic targets. J. Mol. Cell. Cardiol. 70, 92–99. https://doi.org/10.1016/j.yjmcc.2014.01.008 (2014).

17. Abramochkin, D. V., Lozinsky, I. T. & Kamkin, A. Influence of mechanical stress on fibroblast-myocyte interactions in mammalian heart. J. Mol. Cell. Cardiol. 70, 27–36. https://doi.org/10.1016/j.yjmcc.2013.12.020 (2014).
18. Camelliti, P., Borg, T. K. & Kohl, P. Structural and functional characterization of cardiac fibroblasts. *Cardiovasc. Res.* **65**, 40–51. [https://doi.org/10.1016/j.cardiores.2004.08.020](https://doi.org/10.1016/j.cardiores.2004.08.020) (2005).

19. Gaudesius, G., Miragoli, M., Thomas, S. P. & Rohr, S. Coupling of cardiac electrical activity over extended distances by fibroblasts of cardiac origin. *Circ. Res.* **93**, 421–428. [https://doi.org/10.1161/01.RES.0000089285.40661.OC](https://doi.org/10.1161/01.RES.0000089285.40661.OC) (2003).

20. Souders, C. A., Bowers, S. L. & Baudino, T. A. Cardiac fibroblast: The renaissance cell. *Circ. Res.* **105**, 1164–1176. [https://doi.org/10.1161/CIRCRESAHA.109.209989](https://doi.org/10.1161/CIRCRESAHA.109.209989) (2009).

21. Vasquez, C., Benamer, N. & Morley, G. E. The cardiac fibroblast: Functional and electrophysiological considerations in healthy and diseased hearts. *J. Cardiovasc. Pharmacol.**57**, 380–388. [https://doi.org/10.1097/FJC.0b013e31820ca19](https://doi.org/10.1097/FJC.0b013e31820ca19) (2011).

22. Vasquez, C. & Morley, G. E. The origin and arrhythmogenic potential of fibroblasts in cardiac disease. *J. Cardiovasc. Transl. Res.* **5**, 760–767. [https://doi.org/10.1007/s12265-012-9408-1](https://doi.org/10.1007/s12265-012-9408-1) (2012).

23. Pasquier, J. et al. Coculturing with endothelial cells promotes in vitro maturation and electrical coupling of human embryonic stem cell-derived cardiomyocytes. *J. Heart Lung Transpl.* **36**, 684–693. [https://doi.org/10.1016/j.healun.2017.01.001](https://doi.org/10.1016/j.healun.2017.01.001) (2017).

24. Rother, J. et al. Crosstalk of cardiomyocytes and fibroblasts in co-cultures. *Open Biol.* **6**, 150038. [https://doi.org/10.1098/rsob.150038](https://doi.org/10.1098/rsob.150038) (2015).

25. Zamani, M., Karaca, E. & Huang, N. F. Multicellular interactions in 3D engineered myocardial tissue. *Front. Cardiovasc. Med.* **5**, 147. [https://doi.org/10.3389/fcmv.2018.00147](https://doi.org/10.3389/fcmv.2018.00147) (2018).

26. Abecasis, B. et al. Unveiling the molecular crosstalk in a human induced pluripotent stem cell-derived cardiac model. *Biotechnol. Bioeng.* **116**, 1245–1252. [https://doi.org/10.1002/bit.26929](https://doi.org/10.1002/bit.26929) (2019).

27. Dunn, K. K. et al. Coculture of endothelial cells with human pluripotent stem cell-derived cardiac progenitors reveals a differentiation stage-specific enhancement of cardiomyocyte maturation. *Biotechnol. J.* **14**, e1800725. [https://doi.org/10.1002/biot.20180725](https://doi.org/10.1002/biot.20180725) (2019).

28. Zlocichov, S. et al. Electrocortic myofibroblast-to-mycocyte coupling increases propensity to reentrant arrhythmias in two-dimensional cardiac monolayers. *Biophys. J.* **95**, 4469–4480. [https://doi.org/10.1529/biophysj.108.136473](https://doi.org/10.1529/biophysj.108.136473) (2008).

29. Iacquemet, V. & Henriquez, C. S. Loading effect of fibroblast-mycocyte coupling on resting potential, impulse propagation, and repolarization: Insights from a microstructure model. *Am. J. Physiol. Heart Circ. Physiol.* **294**, H2040–H2052. [https://doi.org/10.1152/ajpheart.01298.2007](https://doi.org/10.1152/ajpheart.01298.2007) (2008).

30. Kawatou, M. et al. Modelling Torsade de Pointes arrhythmias in vitro in 3D human iPSC cell-engineered heart tissue. *Nat. Commun.* **8**, 1078. [https://doi.org/10.1038/s41467-017-01125-y](https://doi.org/10.1038/s41467-017-01125-y) (2017).

31. Amano, Y. et al. Development of vascularized iPSC derived 3D-cardiomyocyte tissues by filtration Layer-by-Layer technique and their application for pharmaceutical assays. *Acta Biomater.* **33**, 110–121. [https://doi.org/10.1016/j.actbio.2016.01.033](https://doi.org/10.1016/j.actbio.2016.01.033) (2016).

32. Liu, C. Y., Matsusaki, M. & Akashi, M. Three-dimensional tissue models constructed by cells with nanometer- or micrometer-sized films on the surfaces. *Chem. Rec.* **16**, 783–796. [https://doi.org/10.1002/tcr.201500272](https://doi.org/10.1002/tcr.201500272) (2016).

33. Nishiguchi, A., Yoshiida, H., Matsusaki, M. & Akashi, M. Rapid construction of three-dimensional multilayered tissues with endothelial tube networks by the cell-accumulation technique. *Adv. Mater.* **23**, 3506–3510. [https://doi.org/10.1002/adma.20101787](https://doi.org/10.1002/adma.20101787) (2011).

34. Fridericia, L. S. Die systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken. *Acta Med. Scand.* **53**, 469–486. [https://doi.org/10.1111/j.1600-089X.1920.tb18266.x](https://doi.org/10.1111/j.1600-089X.1920.tb18266.x) (1920).

35. Hayakawa, T. et al. Noninvasive evaluation of contractile behavior of cardiomyocyte monolayers based on motion vector analysis. *Tissue Eng. Part C Methods* **18**, 21–32. [https://doi.org/10.1089/teng.2011.0273](https://doi.org/10.1089/teng.2011.0273) (2012).

Acknowledgements

This research was supported by the SENTAN-JST Program and the Japan Agency for Medical Research and Development under Grant number 17bm0804008. We would like to thank Editage (www.editage.com) for English language editing.

Author contributions

M.T., S.M., and Y.S. conceived the study, designed the experiments, and wrote the manuscript. M.T., E.I., A.H., and N.M. performed the experiments and analyzed the data. M.M., and M.A., conceived the study and interpreted the data.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to Y.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021